Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
QuantumLeap Healthcare Collaborative
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Blueprint Medicines Corporation
Amgen
Eli Lilly and Company
Northwestern University
Stanford University
Actuate Therapeutics Inc.
Taiho Pharmaceutical Co., Ltd.
University of Oklahoma
Northwell Health
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
Emory University
Stanford University
Albert Einstein College of Medicine
Case Comprehensive Cancer Center
Innovent Biologics (Suzhou) Co. Ltd.
GOG Foundation
Roswell Park Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Wisconsin, Madison
Eli Lilly and Company
GOG Foundation
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
NYU Langone Health
City of Hope Medical Center
NYU Langone Health
M.D. Anderson Cancer Center
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
University of Pittsburgh
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fox Chase Cancer Center
National Cancer Institute (NCI)
Roswell Park Cancer Institute
AGO Study Group
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
NYU Langone Health
NYU Langone Health